Does Medicare Cover Kidney Cancer (Renal Cell Carcinoma) Treatment?
Medicare covers kidney cancer treatment comprehensively - but the coverage splits across three different parts of Medicare in ways that surprise many patients. Surgery may fall under Part A or Part B depending on whether you’re admitted to the hospital. IV immunotherapy drugs bill under Part B, while oral targeted therapy pills fall under Part D. And the monthly cost of IV drugs like nivolumab or ipilimumab, without supplemental coverage, can reach $3,000-$5,000 out of pocket per month. Knowing the structure before treatment starts is worth real money.
Renal cell carcinoma (RCC) is the most common kidney cancer, accounting for about 85% of cases. The median age at diagnosis is approximately 65, meaning a significant share of the roughly 82,000 Americans diagnosed each year are on Medicare. This guide walks through every coverage category - surgery, ablation, IV immunotherapy, oral targeted therapy, radiation - with 2026 cost figures and practical strategies to reduce what you pay.
Who Gets Kidney Cancer and Why Medicare Coverage Is Complex
Kidney cancer most often starts in the cells lining the small tubules inside the kidney (hence “renal cell carcinoma”). The main subtypes are:
- Clear cell RCC (about 75% of cases): the most common and the subtype for which most targeted therapies are specifically approved
- Papillary RCC (~15%): subdivided into Type 1 and Type 2; some targeted agents are less effective in papillary RCC
- Chromophobe RCC (~5%): generally slower-growing, good prognosis for localized disease
- Collecting duct and other rare subtypes: less common, may respond differently to standard regimens
About 60% of kidney cancers are found at an early, localized stage - often incidentally on imaging done for another reason. The remaining 40% are regional or metastatic at diagnosis, and that group faces the most complex coverage questions because metastatic RCC treatment involves some of the most expensive drugs in oncology.
For patients who also have chronic kidney disease or a history of kidney stones - two common Medicare-population conditions - understanding how those conditions interact with cancer care adds another layer. See Medicare coverage for chronic kidney disease for how renal function limits drug choices and affects the cost calculus.
Part A: Inpatient Surgery and Hospital Stays
Medicare Part A covers inpatient hospital stays when the physician orders a formal inpatient admission and the patient is expected to need at least two midnights of hospital-level care. Most major kidney cancer surgeries qualify.
Radical nephrectomy: Complete removal of the affected kidney, the ipsilateral adrenal gland (sometimes), and regional lymph nodes. Performed for larger tumors (T2 stage - over 7 cm), locally advanced disease, or when partial nephrectomy is not feasible. Laparoscopic or robotic-assisted approaches are now standard for most patients; open surgery is reserved for very large or complex tumors. A typical laparoscopic radical nephrectomy results in a 2-3 day hospital stay.
Partial nephrectomy (nephron-sparing surgery): Removal of only the tumor and a margin of normal tissue, preserving the remaining kidney. Preferred for T1 stage tumors (7 cm or less), patients with only one kidney, or patients with CKD where losing an entire kidney would cause dialysis-dependency. Robotic-assisted partial nephrectomy is the most common approach at high-volume centers. Hospital stay is typically 1-3 days.
2026 Part A costs for surgery:
- Part A deductible: $1,736 per benefit period
- Days 1-60 of hospitalization: $0 per day after the deductible
- Days 61-90: $434/day coinsurance
- Surgeon fees and anesthesiologist fees are billed separately under Part B (you pay 20% of Medicare-approved amounts)
Medicare Advantage note: Medicare Advantage plans are required to cover everything Original Medicare covers, but may require prior authorization for specific surgical approaches (robotic vs. open) or specific facilities. Obtain written pre-authorization before scheduling.
Part B: Outpatient Surgery, Ablation, and Physician Services
When surgery is performed as an outpatient procedure - or when treatment involves ablation rather than surgical removal - Medicare Part B handles the facility fee and physician services.
Outpatient nephrectomy: Laparoscopic nephrectomy is increasingly performed as a same-day or 23-hour observation procedure at ambulatory surgical centers (ASCs) or hospital outpatient departments (HOPDs). Outpatient classification means Part B covers the facility fee. You pay 20% coinsurance after the annual Part B deductible ($283 in 2026).
Radiofrequency ablation (RFA) and cryoablation: For small renal masses under 3 cm in patients who are not good surgical candidates (due to age, comorbidities, or single-kidney status), minimally invasive ablation techniques destroy the tumor with heat (RFA) or extreme cold (cryoablation). Performed under imaging guidance as an outpatient procedure. Medicare Part B covers these when medically indicated. Your cost: 20% coinsurance after the Part B deductible.
Active surveillance imaging: For very small renal masses (often under 1 cm) in elderly patients, active surveillance with periodic CT or renal ultrasound is a recognized management strategy. Part B covers diagnostic CT scans (20% coinsurance after deductible) and ultrasound. PET scans for staging or restaging metastatic RCC are also covered under Part B when medically necessary.
Physician visits and consultations: Oncology office visits, pre-operative consultations, and follow-up appointments are Part B services. You pay 20% of the Medicare-approved amount after the deductible.
Part B: IV Immunotherapy - The Highest Out-of-Pocket Risk
This is where kidney cancer costs become dramatic for patients without supplemental coverage. IV immunotherapy agents - checkpoint inhibitors like nivolumab and pembrolizumab - are physician-administered infusions billed under Part B. The drugs themselves cost $8,000-$15,000 per dose at list price. Under Original Medicare without a Medigap plan, you pay 20% of the Medicare-allowed amount with no annual out-of-pocket cap.
Current first-line and second-line IV immunotherapy agents for metastatic RCC:
- Nivolumab (Opdivo): A PD-1 checkpoint inhibitor given every 4 weeks. Used as second-line monotherapy and as part of combination regimens
- Ipilimumab (Yervoy): A CTLA-4 checkpoint inhibitor. Combined with nivolumab (the nivolumab/ipilimumab combination - approved by FDA in 2018 for intermediate and poor-risk advanced RCC based on the CheckMate 214 trial). Both drugs bill under Part B; your 20% coinsurance applies to both
- Pembrolizumab (Keytruda): A PD-1 checkpoint inhibitor used in combination with oral TKIs (see Part D section below) for first-line metastatic RCC
- Avelumab (Bavencio): A PD-L1 inhibitor combined with axitinib for favorable-risk advanced RCC
Estimated Part B coinsurance for IV immunotherapy (without Medigap):
Nivolumab (480 mg every 4 weeks): Medicare-allowed amount approximately $6,000-8,000/dose. Your 20% = $1,200-$1,600/dose, or roughly $14,400-$19,200/year.
Nivolumab plus ipilimumab combination induction: Significantly higher during the 4-dose induction phase (ipilimumab given every 3 weeks for 4 doses, then nivolumab alone). Your 20% coinsurance during induction can exceed $2,500-$4,000/dose.
How Medigap Plan G changes this: Medigap Plan G pays 100% of Part B coinsurance after you meet the annual Part B deductible ($283 in 2026). For a patient receiving nivolumab, the annual savings compared to Original Medicare alone can exceed $15,000. See how Medigap plans compare for a full breakdown of Plan G benefits and enrollment timing rules.
Medicare Advantage patients: Many MA plans require prior authorization for IV immunotherapy. PA requirements typically ask for documentation of IMDC (International Metastatic RCC Database Consortium) risk category, prior treatment history, and performance status. Keep copies of all prior authorization approvals and denials - denials can be appealed.
Part D: Oral Targeted Therapy - The TKI Coverage Story
Oral targeted therapy for kidney cancer - tyrosine kinase inhibitors (TKIs), mTOR inhibitors, and the newer HIF-2alpha inhibitor - falls under Medicare Part D prescription drug coverage. This distinction from Part B matters enormously for cost planning.
Key oral agents covered under Part D:
Sunitinib (Sutent): The original TKI for kidney cancer (FDA approved 2006), still used as a first-line option for favorable-risk patients who prefer oral monotherapy. Inhibits VEGFR, PDGFR, and other kinases. Given on a 4-weeks-on, 2-weeks-off schedule. Typical Part D tier: Tier 4-5 specialty. Without the $2,000 annual cap, monthly costs under older plans exceeded $4,000.
Pazopanib (Votrient): Another VEGFR TKI, given daily. Similar efficacy to sunitinib in clinical trials (COMPARZ). Some patients tolerate it better than sunitinib. Part D specialty tier.
Cabozantinib (Cabometyx): A VEGFR/MET/AXL inhibitor with particularly strong activity in papillary RCC (which responds poorly to pure VEGFR TKIs). Approved both as first-line monotherapy and in combination with nivolumab. Part D specialty tier.
Axitinib (Inlyta): Used in combination with pembrolizumab (KEYNOTE-426) or avelumab (JAVELIN RENAL 101) for first-line metastatic RCC. Also used as second-line monotherapy. Part D specialty tier.
Lenvatinib (Lenvima): Combined with everolimus for second-line or with pembrolizumab (CLEAR trial) for first-line. Part D specialty tier.
Everolimus (Afinitor): An mTOR inhibitor used in later lines of therapy after TKI failure. Part D specialty tier.
Belzutifan (Welireg): The newest agent - a first-in-class oral HIF-2alpha inhibitor. FDA approved for two indications: (1) VHL disease-associated RCC, hemangioblastomas, and pancreatic neuroendocrine tumors; (2) advanced RCC after progression on a PD-1/PD-L1 inhibitor and a VEGFR TKI (at least two prior therapies). Part D specialty tier.
2026 Part D cost protection:
The Inflation Reduction Act capped Medicare Part D out-of-pocket drug costs at $2,000 per year beginning in 2025. This applies to all covered Part D drugs combined - not per drug. For a patient on cabozantinib at $12,000/month list price, the most you pay out of pocket across all Part D drugs for the full year is $2,000. This is a transformative change for patients on expensive oral oncology agents.
The $2,000 cap applies to Original Medicare Part D plans. Medicare Advantage plans with built-in drug coverage must meet or exceed this protection.
Low Income Subsidy (LIS/Extra Help): Patients meeting income and asset limits qualify for the Low Income Subsidy program, which reduces or eliminates Part D premiums, deductibles, and copays. The income limit for full LIS is 135% of the federal poverty level. See Medicare Savings Programs for eligibility details - many patients who qualify do not know they can apply.
Combination Regimens: When Part B and Part D Both Apply
Several first-line treatment regimens for metastatic RCC combine an IV checkpoint inhibitor (Part B) with an oral TKI (Part D). The practical implication: your cost-sharing comes from two different parts of Medicare simultaneously.
Pembrolizumab (Part B) + axitinib (Part D): The KEYNOTE-426 regimen. Pembrolizumab given IV every 6 weeks; axitinib taken orally daily. You pay Part B coinsurance on pembrolizumab infusions and Part D cost-sharing on axitinib pills.
Nivolumab (Part B) + cabozantinib (Part D): The CheckMate 9ER regimen. Nivolumab IV every 4 weeks; cabozantinib oral daily. Same split-coverage pattern.
Pembrolizumab (Part B) + lenvatinib (Part D): The CLEAR trial regimen. Pembrolizumab IV; lenvatinib oral daily.
What this means for your budget: If you have Medigap Plan G, the Part B component is covered after your annual deductible. The Part D component hits the $2,000 annual cap. If you have Medicare Advantage, both components require navigating MA prior authorization rules - which may differ for the two drugs even when they’re part of the same FDA-approved regimen.
Radiation Therapy for Kidney Cancer
Classic RCC is considered relatively radiation-resistant in the primary tumor, so external beam radiation to the kidney is rarely used as curative therapy. However, radiation plays an important role in metastatic disease management:
SBRT (stereotactic body radiation therapy) for oligometastatic disease: When RCC spreads to the lungs, lymph nodes, or other organs and the number of metastases is small (typically 1-5 sites), SBRT can ablate individual metastatic sites while systemic therapy controls the broader disease. Medicare Part B covers SBRT; you pay 20% coinsurance.
Palliative radiation for bone metastases: RCC frequently metastasizes to bone. Bone metastases cause pain and risk of fractures. A short course of external beam radiation (typically 5-10 fractions) covered under Part B provides effective pain relief. Your cost: 20% coinsurance.
Spine radiosurgery (CyberKnife, Gamma Knife): For spinal metastases or brain metastases from RCC, stereotactic radiosurgery delivers a high-dose, precisely targeted treatment. Part B covers these procedures.
2026 Medicare Cost Summary for Kidney Cancer
| Service | Medicare Part | Your Cost (Original Medicare) |
|---|---|---|
| Radical or partial nephrectomy (inpatient) | Part A | $1,736 deductible + $0/day for days 1-60 |
| Nephrectomy (outpatient/ASC) | Part B | 20% after $283 deductible |
| Surgeon and anesthesiologist fees | Part B | 20% coinsurance |
| Ablation (RFA or cryoablation) | Part B | 20% coinsurance |
| CT scans, PET scans, MRI | Part B | 20% coinsurance |
| IV immunotherapy (nivolumab, ipilimumab, pembrolizumab) | Part B | 20% coinsurance (no annual cap) |
| Oral TKIs (sunitinib, cabozantinib, axitinib, etc.) | Part D | Up to $2,000/year total Part D cap |
| Belzutifan (Welireg) | Part D | Up to $2,000/year total Part D cap |
| SBRT for metastatic lesions | Part B | 20% coinsurance |
| Palliative radiation for bone metastases | Part B | 20% coinsurance |
With Medigap Plan G: The Part A deductible is covered. All Part B coinsurance is covered after the Part B deductible ($283). Part D cap stays at $2,000. Annual maximum out-of-pocket is predictable and low for most patients.
Without Medigap: IV immunotherapy alone can cost $15,000-$25,000/year in Part B coinsurance with no cap.
Biomarker Testing and Genetic Considerations
Medicare Part B covers diagnostic tests considered medically necessary for treatment decision-making:
VHL gene mutation testing: The VHL tumor suppressor gene is mutated in about 90% of sporadic clear cell RCC tumors. Identifying VHL mutation status is relevant to belzutifan eligibility and may guide treatment sequencing. Next-generation sequencing (NGS) panels covering VHL and other relevant genes are covered under Part B when ordered by the treating oncologist.
PD-L1 expression testing: Some combination regimens (avelumab/axitinib, pembrolizumab combinations) may use PD-L1 status as a clinical factor. PD-L1 IHC testing on tumor tissue is covered under Part B when medically necessary.
Germline VHL syndrome testing: Patients with bilateral RCC, early-onset RCC (under 46), or family history suggesting VHL disease should be referred for germline genetic counseling. If germline VHL mutation is confirmed, belzutifan is specifically approved for the VHL disease indication. Genetic counseling is covered under Part B.
5 Steps to Navigate Kidney Cancer Coverage
Step 1: Confirm your surgery setting before scheduling. Ask your urologist whether the nephrectomy will be classified as inpatient (Part A) or outpatient (Part B). If inpatient, your Part A deductible applies. If outpatient, your Part B deductible and 20% coinsurance apply. The classification affects both your cost and SNF eligibility after surgery.
Step 2: Get prior authorization in writing for all systemic therapy. For Medicare Advantage patients especially, IV immunotherapy and oral TKIs require prior authorization. Obtain written approval before the first infusion or the first fill. Keep a copy. If denied, file a formal appeal within 60 days - denials for FDA-approved, guideline-concordant regimens are frequently overturned.
Step 3: Understand your Part B exposure before starting IV immunotherapy. If you have Original Medicare without a Medigap plan, calculate your projected 20% coinsurance on the planned regimen. For nivolumab/ipilimumab induction, this can exceed $4,000/month during induction. If the numbers are significant, evaluate Medigap enrollment options - though note that outside of initial Medicare enrollment windows, medical underwriting may apply.
Step 4: Maximize the $2,000 Part D cap. If you’re on an oral TKI, you will likely reach the $2,000 annual out-of-pocket cap well before year-end. After that point, your Part D drugs cost $0 for the rest of the calendar year. Track your spending at the pharmacy or via your plan’s online portal - some patients don’t realize they’ve hit the cap and continue paying unnecessarily.
Step 5: Check LIS/Extra Help eligibility. The Low Income Subsidy program can reduce Part D costs to nominal copays and eliminate the Part D premium. If your income is at or below 150% of the federal poverty level, apply through Social Security Administration (ssa.gov). The application is free and there is no penalty for applying and not qualifying.
Frequently Asked Questions
Does Medicare cover robotic-assisted nephrectomy? Yes. Medicare covers robotic-assisted partial or radical nephrectomy when medically indicated. The cost-sharing is the same as for open surgery - Part A if inpatient, Part B if outpatient. Some Medicare Advantage plans require prior authorization specifically for robotic surgery; confirm before scheduling.
Is sunitinib (Sutent) covered by Medicare Part D? Yes. Sunitinib is covered as a specialty-tier drug under Medicare Part D. With the 2026 $2,000 annual out-of-pocket cap, the most you will pay across all Part D drugs in the year is $2,000, regardless of sunitinib’s list price. Contact your plan to confirm the tier and confirm the drug is on your formulary before the first fill.
Is cabozantinib (Cabometyx) covered by Medicare? Yes, under Part D as an oral specialty drug. The $2,000 annual cap applies. Cabozantinib is also FDA-approved in combination with nivolumab (Opdivo, Part B) for first-line metastatic RCC - in that combination, you’re drawing on both Part B and Part D simultaneously.
Does Medicare cover nivolumab (Opdivo) for kidney cancer? Yes. Nivolumab is covered under Part B as a physician-administered infusion. Without Medigap, you pay 20% of the Medicare-allowed amount per dose, with no annual cap. With Medigap Plan G, your Part B coinsurance is covered after the Part B deductible. Nivolumab monotherapy is approved for previously treated advanced RCC; nivolumab plus ipilimumab is approved first-line for intermediate and poor-risk advanced RCC.
What is belzutifan (Welireg) and does Medicare cover it? Belzutifan (Welireg) is an oral HIF-2alpha inhibitor covered under Part D. It is approved for two indications: (1) adults with VHL disease-associated RCC, CNS hemangioblastomas, or pancreatic neuroendocrine tumors; and (2) adults with previously treated advanced RCC who have received a PD-1/L1 inhibitor and a VEGFR TKI. It applies to the $2,000 annual Part D cap.
Will Medicare Advantage require prior authorization for kidney cancer immunotherapy? Very likely yes. Prior authorization is standard for IV checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab) and oral TKIs under Medicare Advantage plans. Required documentation typically includes the treating oncologist’s attestation of the clinical indication, IMDC risk classification, and documentation of prior therapy (for second-line agents). Submit requests as early as possible to avoid treatment delays.
Does Medicare cover CT scans to monitor kidney cancer recurrence after surgery? Yes. Surveillance imaging (CT scans of the chest, abdomen, and pelvis) is a standard part of post-nephrectomy follow-up and is covered under Part B when ordered by a treating physician for cancer monitoring. You pay 20% coinsurance after the Part B deductible.
How does kidney cancer treatment interact with existing chronic kidney disease? Several oral TKIs are dosed based on kidney function (eGFR). Some agents - notably sunitinib and other VEGFR inhibitors - can cause proteinuria and hypertension, which may worsen underlying CKD. Belzutifan may cause anemia (erythropoiesis-related, related to its EPO-suppressive mechanism). Your oncologist will coordinate with nephrology if you have baseline CKD. See Medicare coverage for chronic kidney disease for how dialysis and transplant interact with cancer treatment coverage.
Sources
- Medicare Coverage for Kidney Cancer - CMS
- Nivolumab + Ipilimumab for Advanced RCC - FDA Approval (2018)
- Belzutifan (Welireg) FDA Approval for VHL Disease
- Belzutifan FDA Approval for Metastatic RCC (2023)
- Medicare Part D $2,000 Out-of-Pocket Cap - CMS
- Low Income Subsidy (Extra Help) Program - SSA
- Kidney Cancer Statistics - National Cancer Institute SEER